Lakefront Biotherapeutics Stock (NASDAQ:LKFT)
Previous Close
$33.93
52W Range
$25.68 - $36.24
50D Avg
$30.26
200D Avg
$29.89
Market Cap
$2.23B
Avg Vol (3M)
$286.78K
Beta
0.12
Div Yield
-
LKFT Company Profile
Lakefront Biotherapeutics NV, formerly Galapagos NV, is a biotechnology company that focuses on transforming patient outcomes through scientific innovation. It is dedicated to building a pipeline of medicines for patients with serious diseases in therapeutic areas of unmet need, prioritizing oncology and immunology & inflammation programs. The company's clinical-stage portfolio is anchored by potential first-in-class treatments for autoimmune diseases.
LKFT Performance
Peer Comparison
| Ticker | Company |
|---|---|
| SLS | SELLAS Life Sciences Group, Inc. |
| CBIO | Crescent Biopharma, Inc. |
| TRAX | First Tracks Biotherapeutics Inc |
| MLTX | MoonLake Immunotherapeutics |
| NBP | NovaBridge Biosciences |
| STTK | Shattuck Labs, Inc. |
| IOVA | Iovance Biotherapeutics, Inc. |
| GNLX | Genelux Corporation |
| SNDX | Syndax Pharmaceuticals, Inc. |
| AURA | Aura Biosciences, Inc. |